<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375583</url>
  </required_header>
  <id_info>
    <org_study_id>999906244</org_study_id>
    <secondary_id>06-I-N244</secondary_id>
    <nct_id>NCT00375583</nct_id>
  </id_info>
  <brief_title>Effect of Albendazole Dose on Clearance of Filarial Worms</brief_title>
  <official_title>Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tuberculosis Research Centre, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study, conducted in Chennai, India, will determine whether a new treatment regimen of&#xD;
      albendazole and diethylcarbamazine for lymphatic filariasis can eliminate the disease more&#xD;
      quickly than the standard regimen. Lymphatic filariasis is caused by infection with very&#xD;
      small filarial worms, particulalry Wuchereria bancroti, that are spread by mosquitoes. The&#xD;
      infection can lead to swelling of the arms, legs, breast and scrotum and can progress to&#xD;
      permanent swelling of the legs or arms called elephantiasis. The study will see if a higher&#xD;
      and more frequent dose of albendazole is better at clearing filarial worms from the blood&#xD;
      than the current treatment.&#xD;
&#xD;
      Healthy people between 18 and 55 years of age who are in good health and who are infected&#xD;
      with Wuchereria bancrofti may be eligible for this 28-month study. Candidates must be willing&#xD;
      to spend 4 days in the Government General Hospital in Chennai, India, at the beginning of the&#xD;
      study. They are screened with a medical history, a brief physical examination, ultrasound&#xD;
      (picture generated by sound waves) of the groin or chest, and blood tests to check for&#xD;
      infection with Wuchereria bancrofti and to measure white blood cell counts.&#xD;
&#xD;
      Participants undergo the following procedures:&#xD;
&#xD;
      -4-day hospitalization&#xD;
&#xD;
      Random assignment to receive either standard treatment (400 mg albendazole and 300 mg DEC&#xD;
      given once a year for 2 years) or the experimental regimen (800 mg albendazole and 300 mg DEC&#xD;
      given twice a year for 2 years)&#xD;
&#xD;
      Urine pregnancy test for women of childbearing age&#xD;
&#xD;
      Receive first treatment dose&#xD;
&#xD;
      Monitoring for symptoms&#xD;
&#xD;
      -6-month outpatient visit&#xD;
&#xD;
      Short history, physical examination and blood test&#xD;
&#xD;
      Second treatment dose for subjects receiving 800 mg albendazole&#xD;
&#xD;
      Urine pregnancy test for women of childbearing age&#xD;
&#xD;
      -1-year outpatient visit&#xD;
&#xD;
      Short history, physical examination and blood test&#xD;
&#xD;
      Second or third treatment dose, depending on treatment group&#xD;
&#xD;
      Repeat ultrasound in subjects whose first ultrasound detected adult worm&#xD;
&#xD;
      Urine pregnancy test for women of childbearing age&#xD;
&#xD;
      -18-month outpatient visit&#xD;
&#xD;
      Short history, physical examination and blood test&#xD;
&#xD;
      Fourth treatment dose for subjects receiving 800 mg albendazole&#xD;
&#xD;
      Urine pregnancy test for women of childbearing age&#xD;
&#xD;
      -24-month outpatient visit&#xD;
&#xD;
      Short history, physical examination and blood test&#xD;
&#xD;
      Final dose of albendazole and DEC at standard doses&#xD;
&#xD;
      Repeat ultrasound in subjects whose first ultrasound detected adult worms&#xD;
&#xD;
      Urine pregnancy test for women of childbearing age&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Albendazole and diethylcarbamazine (DEC) are currently used in combination for annual mass&#xD;
      treatment of lymphatic filariasis in all parts of the world except Africa. Although the drugs&#xD;
      have been donated, the cost of such programs is very high and has proven to be a major&#xD;
      impediment to the success of programs in many countries with limited financial resources.&#xD;
      Data from albendazole treatment of other filarial infections and one study comparing single&#xD;
      to multi-dose DEC/albendazole in lymphatic filariasis suggest that increased dose and/or&#xD;
      frequency of albendazole dosing may be more effective in clearing microfilariae. In this&#xD;
      study, 50 volunteers with microfilaremic Wuchereria bancrofti infection will be randomized to&#xD;
      receive standard annual therapy (albendazole 400 mg + DEC 300 mg) or semiannual therapy with&#xD;
      an increased albendazole dose (albendazole 800 mg + DEC 300 mg). Microfilarial levels, as&#xD;
      well as measures of adult worm burden (circulating antigen, ultrasound identification of&#xD;
      adult worm nests) will be followed every six months for two years to determine whether the&#xD;
      higher dose, more frequent regimen is more effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 9, 2006</start_date>
  <completion_date type="Actual">April 28, 2011</completion_date>
  <primary_completion_date type="Actual">April 28, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Microfilarial levels.</measure>
    <time_frame>12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult worm burden.</measure>
    <time_frame>12 and 24 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <condition>Wuchereria Bancrofti Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEC/Albendazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA (SCREENING):&#xD;
&#xD;
        Age 18 years to 55 years inclusive.&#xD;
&#xD;
        Both genders.&#xD;
&#xD;
        Not pregnant or breastfeeding by history.&#xD;
&#xD;
        If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the&#xD;
        Government General Hospital, Chennai India.&#xD;
&#xD;
        If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2&#xD;
        years.&#xD;
&#xD;
        If selected, agree to have blood stored for future studies.&#xD;
&#xD;
        Ability to understand and sign the informed consent.&#xD;
&#xD;
        EXCLUSION CRITERIA (SCREENING):&#xD;
&#xD;
        Non-volunteers.&#xD;
&#xD;
        Age less than 18 years or greater than 55 years.&#xD;
&#xD;
        Pregnant or breastfeeding by history.&#xD;
&#xD;
        INCLUSION (TREATMENT):&#xD;
&#xD;
        Age 18 years to 55 years.&#xD;
&#xD;
        Men and non-pregnant or non-breastfeeding women.&#xD;
&#xD;
        Microfilarial levels greater than 50 mf/ml.&#xD;
&#xD;
        Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital,&#xD;
        Chennai India.&#xD;
&#xD;
        Willingness to undergo nighttime blood draws every 6 months for 2 years.&#xD;
&#xD;
        Ability to understand and sign the informed consent.&#xD;
&#xD;
        Hb levels for inclusion greater than 9 g/dL.&#xD;
&#xD;
        Normal Cr, ALT.&#xD;
&#xD;
        Willingness to have blood stored for future studies.&#xD;
&#xD;
        EXCLUSION (TREATMENT):&#xD;
&#xD;
        Non-volunteers.&#xD;
&#xD;
        Age less than 18 years or greater than 55 years.&#xD;
&#xD;
        Pregnancy or breast-feeding.&#xD;
&#xD;
        Hgb less than or equal to 9 g/dL.&#xD;
&#xD;
        Cr greater than 1.2/100 ml.&#xD;
&#xD;
        ALT greater than 30 U.&#xD;
&#xD;
        Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a&#xD;
        week of each drug administration.&#xD;
&#xD;
        Temperature greater than 37.5 degrees C.&#xD;
&#xD;
        Serious medical illness.&#xD;
&#xD;
        History of benzimidazole allergy.&#xD;
&#xD;
        History of DEC allergy.&#xD;
&#xD;
        Use of albendazole or DEC within past 6 months.&#xD;
&#xD;
        Unwillingness to comply with required study visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tuberculosis Research Centre</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Adjepon-Yamoah KK, Edwards G, Breckenridge AM, Orme ML, Ward SA. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man. Br J Clin Pharmacol. 1982 Jun;13(6):829-34.</citation>
    <PMID>7093114</PMID>
  </reference>
  <reference>
    <citation>Andrade LD, Medeiros Z, Pires ML, Pimentel A, Rocha A, Figueredo-Silva J, Coutinho A, Dreyer G. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):319-21.</citation>
    <PMID>7660449</PMID>
  </reference>
  <reference>
    <citation>Amaral F, Dreyer G, Figueredo-Silva J, Noroes J, Cavalcanti A, Samico SC, Santos A, Coutinho A. Live adult worms detected by ultrasonography in human Bancroftian filariasis. Am J Trop Med Hyg. 1994 Jun;50(6):753-7.</citation>
    <PMID>8024070</PMID>
  </reference>
  <verification_date>April 28, 2011</verification_date>
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>Thomas B. Nutman, M.D./National Institute of Allergy and Infectious Diseases</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Lymphatic Filariasis</keyword>
  <keyword>Diethylcarbamazine</keyword>
  <keyword>Microfilariae</keyword>
  <keyword>Helminths</keyword>
  <keyword>Nematode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

